-
1.发明授权Preparation of enzymatically active sponges or foams for detoxification of hazardous compounds 失效制备用于有毒化合物解毒的酶活性海绵或泡沫公开(公告)号：US06642037B2
公开(公告)日：2003-11-04
申请号：US09558512
申请日：2000-04-26
申请人： Richard K. Gordon , Bhupendra P. Doctor , Ashima Saxena , Shawn R. Feaster , Donald Maxwell , Michelle Ross , David Lenz , Keith Lejeune , Alan Russell
发明人： Richard K. Gordon , Bhupendra P. Doctor , Ashima Saxena , Shawn R. Feaster , Donald Maxwell , Michelle Ross , David Lenz , Keith Lejeune , Alan Russell
IPC分类号： C12N1104
CPC分类号： A62D3/00 , A61L2/16 , A61L2/235 , A62D3/02 , A62D2101/02 , A62D2101/26 , A62D2101/28 , C08G18/10 , C08G2101/0083 , C12N11/04 , C12N11/18 , C08G18/3821
摘要： An enzymatically active reusable sponge or foam, capable of regeneration with oximes, made of a polymer such as polyurethane is prepared for detoxification of hazardous compounds such as organophosphorus and organosulfur compounds. The foam or sponge contains a plurality of enzymes including enzymes selected from acetylcholinesterase, butyrylcholinesterase, triesterase, pseudocholinesterase, organophosphate hydrase, phosphotriesterase, paraoxonase and organophosphorus and organosulfur hydrolyzing enzymes. The sponge or foam may additionally contain activated carbon and an enzyme reactivation compound. A kit can be formed containing the sponge or foam and the compound for enzyme reactivation. The enzymatically active foam or sponge may be prepared using a two chamber device where enzymes and prepolymer are passed from separate chambers into a static mixing stator and are subjected to low shear mixing and extrusion to form by the sponge or foam.
摘要翻译： 制备能够由诸如聚氨酯的聚合物制成的能够用肟再生的酶活性可重复使用的海绵或泡沫，用于有机磷和有机硫化合物等有害化合物的解毒。 泡沫或海绵含有多种酶，包括选自乙酰胆碱酯酶，丁酰胆碱酯酶，三酯酶，假胆碱酯酶，有机磷酸盐水解酶，磷酸三酯酶，对氧磷酶和有机磷和有机硫水解酶的酶。 海绵或泡沫可另外含有活性炭和酶再活化化合物。 可以形成包含海绵或泡沫的试剂盒和用于酶再活化的化合物。 酶活性泡沫或海绵可以使用两室装置制备，其中酶和预聚物从分离的室进入静态混合定子，并经受低剪切混合和挤出以由海绵或泡沫形成。
-
公开(公告)号：US06406876B1
公开(公告)日：2002-06-18
申请号：US09558511
申请日：2000-04-26
申请人： Richard K. Gordon , Bhupendra P. Doctor , Ashima Saxena , Shawn R. Feaster , Donald Maxwell , Michelle Ross , David Lenz , Keith LeJeune , Alan Russell
发明人： Richard K. Gordon , Bhupendra P. Doctor , Ashima Saxena , Shawn R. Feaster , Donald Maxwell , Michelle Ross , David Lenz , Keith LeJeune , Alan Russell
IPC分类号： C12Q146
CPC分类号： C12Q1/34 , C12Q1/26 , C12Q1/28 , C12Q1/42 , C12Q1/44 , C12Q1/46 , Y10S435/963 , Y10S435/97
摘要： Methods, compositions and materials useful in the detection of organophosphorous and organosulfur compounds are disclosed. In particular, biosensors wherein a porous or a non-porous support having an enzyme immobilized upon or within are disclosed. The biosensors exhibit enzymatic stability at extreme temperatures and/or denaturing conditions, and similar kinetic characteristics of the soluble form of the enzymes utilized. The enzyme does not leach from the porous or non-porous support and the material retains enzymatic activity after prolonged storage. Differential biosensors are also disclosed.
摘要翻译： 公开了用于检测有机磷和有机硫化合物的方法，组合物和材料。 特别地，公开了其中固定有或内部固定有酶的多孔或无孔载体的生物传感器。 生物传感器在极端温度和/或变性条件下表现出酶稳定性，以及所用酶的可溶形式的类似动力学特征。 该酶不会从多孔或非多孔载体中浸出，并且材料在长时间储存后保留酶活性。 还公开了差示生物传感器。
-
公开(公告)号：US06746850B2
公开(公告)日：2004-06-08
申请号：US09848370
申请日：2001-05-04
IPC分类号： C12Q146
CPC分类号： C12Q1/005 , C12Q1/46 , G01N33/557 , G01N33/567
摘要： An assay for detecting, measuring, or monitoring the activity or concentration of at least two proteins that have similar or overlapping properties is disclosed. The assay comprises first determining the sensitivity coefficients of the substrates for each of the proteins in which the concentrations are to be determined. This method may be used for detecting, measuring, or monitoring the activity and concentration of AChE, BChE, or both in a test sample which test sample may be whole and unprocessed blood or tissue. Also disclosed are methods of using the assay to detect a subject's exposure to an agent which affects cholinesterase, determine the efficacy or progress of a treatment, determine the amount of protection provided against exposure to an agent which affects cholinesterase, or both, screen a subject for having a drug sensitivity or a particular disease, detect a change in red blood cell count of a subject, determine whether a candidate compound affects cholinesterase. Also disclosed are devices and kits for detecting, measuring, or monitoring the activities and concentrations of AChE, BChE, or both.
-
4.发明授权Liposomes containing novel targeting and/or fusogenic peptides, preparations containing them and therapeutic use thereof 失效含有新靶向和/或融合肽的脂质体，含有它们的制剂及其治疗用途公开(公告)号：US07741431B2
公开(公告)日：2010-06-22
申请号：US11339404
申请日：2006-01-25
IPC分类号： A61K38/00 , A61K38/04 , C07K2/00 , C07K4/00 , C07K5/00 , C07K7/00 , C07K14/00 , C07K16/00 , C07K17/00
CPC分类号： A61K9/1272 , C07K14/005 , C07K14/57536 , C12N2760/16022
摘要： A novel targeting peptide from the C-terminal of endothelin and/or a novel fusogenic peptide from hemagglutinin are optionally conjugated to the carboxy group of 1,2-dioleoyl-sn-glycero-3-succinate and incorporated into liposomes for therapeutic treatment. The novel targeting peptide directs liposomes to lung cells, and, therefore, is useful for delivering liposomes encapsulating cholinesterase genes, particularly, the human serum butyryl cholinesterase (Hu BChE) gene, as a treatment against nerve agents. It is emphasized that this abstract is provided to comply with the rules requiring an abstract which will allow a searcher or other reader quickly to ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the appended issued claims. 37 CFR §1.72(b).
摘要翻译： 任选地，将来自血管凝血酶的C端的新型靶向肽和/或来自血凝素的新的融合肽缀合到1,2-二油酰-sn-甘油基-3-琥珀酸酯的羧基上并且并入脂质体中进行治疗。 新型靶向肽将脂质体引导至肺细胞，因此可用于递送包封胆碱酯酶基因的脂质体，特别是人血清丁酰胆碱酯酶（Hu BChE）基因作为神经药物的治疗。 要强调的是，该摘要被提供以符合要求抽象的规则，这将允许搜索者或其他读者快速地确定技术公开的主题。 提交它的理解是，它不会用于解释或限制所附权利要求的范围或含义。 37 CFR§1.72（b）。
-
5.发明申请Liposomal drug delivery constructs targeted by lipid-conjugated peptide ligands 审中-公开由脂质缀合的肽配体靶向的脂质体递送构建体公开(公告)号：US20090220587A1
公开(公告)日：2009-09-03
申请号：US12379096
申请日：2009-02-12
CPC分类号： A61K9/1272 , A61K9/19 , A61K38/00 , C07K14/57536
摘要： A receptor ligand is conjugated to a lipid-soluble moiety, thereby allowing effective delivery of the peptide ligand to a target cell in the form of a liposome complex. The ligand brings the liposome in proximity to the target cell, facilitating the fusion of the liposome with an endosome of the cellular target to release the payload into the cytoplasm. The liposome itself packages drugs or other therapeutics that are delivered to the interior of the cell upon fusion of the liposome.
摘要翻译： 受体配体与脂溶性部分缀合，从而允许肽配体以脂质体复合物的形式有效递送到靶细胞。 配体使脂质体接近靶细胞，促进脂质体与细胞靶标的内体的融合，以将有效负载释放到细胞质中。 脂质体本身包装在脂质体融合后递送至细胞内部的药物或其它治疗剂。
-
6.发明授权Large-scale production of human serum butyrylcholinesterase as a bioscavenger 失效大规模生产人血清丁酰胆碱酯酶作为生物识别剂公开(公告)号：US07754461B2
公开(公告)日：2010-07-13
申请号：US11733246
申请日：2007-04-10
申请人： Bhupendra P. Doctor , Ashima Saxena , Wei Sun , Chunyuan Luo , Prasanthi Tipparaju , Irwin Koplovitz , David E. Lenz , Michelle C. Ross
发明人： Bhupendra P. Doctor , Ashima Saxena , Wei Sun , Chunyuan Luo , Prasanthi Tipparaju , Irwin Koplovitz , David E. Lenz , Michelle C. Ross
摘要： Disclosed herein are methods for the large-scale preparation of human butyrylcholinesterase (HuBChE) preparations from Cohn Fraction IV-4. As disclosed, the methods provide HuBChE preparations that are about 99% or more pure with recovery yields of about 60%. Also disclosed are the pharmacokinetics, safety and toxicity, stability and efficacy of the HuBChE preparations.
摘要翻译： 本文公开了从Cohn Fraction IV-4大规模制备人丁酰胆碱酯酶（HuBChE）制剂的方法。 如所公开的，所述方法提供了约99％或更高纯度的HuBChE制剂，回收率为约60％。 还公开了HuBChE制剂的药代动力学，安全性和毒性，稳定性和功效。
-
7.发明授权Previns as specific inhibitors and therapeutic agents for botulinum toxin B and tetanus neurotoxins 失效前列腺素作为肉毒杆菌毒素B和破伤风神经毒素的特异性抑制剂和治疗剂公开(公告)号：US07235521B1
公开(公告)日：2007-06-26
申请号：US09979101
申请日：2000-05-15
IPC分类号： A61K38/00
CPC分类号： C12Q1/37 , G01N2333/95 , G01N2500/00
摘要： The compounds of the invention are generally described by the formula (1): B1Z*2B3Z*4X*5Q6F7X8X9X10X11, (2): B1X2X3X4X5Q6F7X8X9X10X11, or (3): B1X2B3X4Z5Q6F7Z8X9X10X11 and the salts, esters, amides, and acyl forms thereof. Each position represented by a letter indicates a single amino acid residue: B is a basic or polar/large amino acid or a modified form thereof; X is a small or hydrophobic amino acid or a modified form thereof; X* is a small or polar/large amino acid or a modified form thereof; Z is a polar/large or hydrophobic amino acid or a modified form thereof; Z* is Proline or a polar/large or hydrophobic amino acid or a modified form thereof. As described below, one or more of the peptide linkages between the amino acid residues may be replaced by a peptide linkage mimic. These compounds may be used as molecular building blocks to create compounds that are optimized for inhibiting the protease activity of Botulinum B and tetanus toxins.
摘要翻译： 本发明的化合物通常由式（1）描述：B 1 Z * 2 B 3 Z * 4 < 5×6×6×6××××××××××××××××××××××××××××××××××××××××××< （2）：B 1 X 2 X 3 X 2 X 2 X 3 5 5 5 或（3）：B 1 X 2 B 3 3 5 X 5 5 5 它们的盐，酯，酰胺和酰基形式。 由字母表示的每个位置表示单个氨基酸残基：B是碱性或极性/大氨基酸或其修饰形式; X是小或疏水性氨基酸或其修饰形式; X *是小或极/大氨基酸或其修饰形式; Z是极性/大或疏水性氨基酸或其修饰形式; Z *是脯氨酸或极性/大或疏水性氨基酸或其修饰形式。 如下所述，氨基酸残基之间的一个或多个肽键可以被肽键模拟物代替。 这些化合物可用作分子结构单元以产生针对抑制肉毒杆菌B和破伤风毒素的蛋白酶活性而优化的化合物。
-
8.发明授权公开(公告)号：US07375079B2
公开(公告)日：2008-05-20
申请号：US11268757
申请日：2005-11-04
IPC分类号： A61K38/00
CPC分类号： C07K7/06 , A61K38/00 , C07K7/08 , C07K7/22 , C07K14/8146
摘要： The compounds of the invention are generally described by the formula: B1Z*2B3Z*4X*5Q6F7X8X9X10X11, (1) B1X2X3X4X5Q6F7X8X9X10X11, or (2) B1Z2B3X4Z5Q6F7Z8X9X10X11 (3) and the salts, esters, amides, and acyl forms thereof. Each position represented by a letter indicates a single amino acid residue: B is a basic of polar/large amino acid or a modified form thereof; X is a small or hydrophobic amino acid or a modified form thereof; X* is a small or polar/large amino acid or a modified form thereof; Z is a polar/large or hydrophobic amino acid or a modified form thereof; Z* is Proline or a polar/large of hydrophobic amino acid or a modified form thereof. As described below, one or more of the peptide linkages between the amino acid residues may be replaced by a peptide linkage mimic. These compounds may be used as molecular building blocks to create compounds that are optimized for inhibiting the protease activity of Botulinum b and tetanus toxins.
-
9.发明授权Previns as specific inhibitors and therapeutic agents for Botulinum toxin B and Tetanus neurotoxins 失效前列腺素作为肉毒杆菌毒素B和破伤丹神经毒素的特异性抑制剂和治疗剂公开(公告)号：US06573244B1
公开(公告)日：2003-06-03
申请号：US09570022
申请日：2000-05-12
IPC分类号： A61K3800
CPC分类号： C07K7/06 , A61K38/00 , C07K7/08 , C07K7/22 , C07K14/8146
摘要： The compounds of the invention are generally described by the formula: B1Z*2B3Z*4X*5Q6F7X8X9X10X11 (1), B1X2X3X4X5Q6F7X8X9X10X11 (2), or B1X2B3X4Z5Q6F7Z*8X9X10X11 (3) and the salts, esters, amides, and acyl forms thereof. Each position represented by a letter indicates a single amino acid residue: B is a basic or polar/large amino acid or a modified form thereof; X is a small or hydrophobic amino acid or a modified form thereof; X* is a small or polar/large amino acid or a modified form thereof; Z is a polar/large or hydrophobic amino acid or a modified form thereof; Z* is Proline or a polar/large or hydrophobic amino acid or a modified form thereof. As described below, one or more of the peptide linkages between the amino acid residues may be replaced by a peptide linkage mimic. These compounds may be used as molecular building blocks to create compounds that are optimized for inhibiting the protease activity of Botulinum B and tetanus toxins.
摘要翻译： 本发明的化合物通常用下式描述：或其盐，酯，酰胺及其酰基形式。 由字母表示的每个位置表示单个氨基酸残基：B是碱性或极性/大氨基酸或其修饰形式; X是小或疏水性氨基酸或其修饰形式; X *是小或极/大氨基酸或其修饰形式; Z是极性/大或疏水性氨基酸或其修饰形式; Z *是脯氨酸或极性/大或疏水性氨基酸或其修饰形式。 如下所述，氨基酸残基之间的一个或多个肽键可以被肽键模拟物代替。这些化合物可以用作分子结构单元以产生针对抑制肉毒杆菌B和破伤风的蛋白酶活性而优化的化合物 毒素
-
10.发明授权Buforin I as a specific inhibitor and therapeutic agent for botulinum toxin B and tetanus neurotoxins 失效Buforin I作为特异性抑制剂和肉毒杆菌毒素B和破伤风神经毒素的治疗剂公开(公告)号：US06713444B1
公开(公告)日：2004-03-30
申请号：US09570023
申请日：2000-05-12
IPC分类号： A61K3800
CPC分类号： C07K14/8146 , A61K38/00
摘要： The compounds of the invention are generally described by the formula: X1X2B3X4B5X*6X7X8 B9X10B11X12B13X14 B15X16B17X*18X*19B20 X21X22X23Q24F25Z*26X27 X28B29X30B31B32X33X34 B35B36X37Z38Z39 (1) and the salts, esters, amides, and acyl forms thereof. Up to 15 amino acids may be truncated from the N-terminus and up to 6 amino acids may be truncated from the C-terminus. Each position represented by a letter indicates a single amino acid residue wherein B is a basic or polar/large amino acid or a modified form thereof; X is a small or hydrophobic amino acid or a modified form thereof; X* is a small or polar/large amino acid or a modified form thereof; Z is a polar/large or hydrophobic amino acid or a modified form thereof; Z* is Proline or a polar/large or hydrophobic amino acid or a modified form thereof. These compounds may be used to inhibit the protease activity of Botulinum B and tetanus toxins.
摘要翻译： 本发明的化合物通常用下式描述：及其盐，酯，酰胺及其酰基形式。 可以从N末端截断至多15个氨基酸，并且可以从C末端截断至多6个氨基酸。 由字母表示的每个位置表示单个氨基酸残基，其中B是碱性或极性/大氨基酸或其修饰形式; X是小或疏水性氨基酸或其修饰形式; X *是小或极/大氨基酸或其修饰形式; Z是极性/大或疏水性氨基酸或其修饰形式; Z *是脯氨酸或极性/大或疏水性氨基酸或其修饰形式。 这些化合物可用于抑制肉毒杆菌B和破伤风毒素的蛋白酶活性。
-
-
-
-
-
-
-
-
-
搜索结果
17 条记录 (耗时 0.054 秒)
